Sugi Predict

Sugi Predict / Compounds / SCHEMBL84395

SCHEMBL84395

SCHEMBL84395

CC(C)c1ccc(O)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYR P14679 3/20 0.40
▸ PTGS1 P23219 2/20 0.40
▸ TRPA1 O75762 1/20 0.40
▸ CACNA1C Q13936 1/20 0.40
▸ HTT P42858 2/20 0.39
▸ HIF1A Q16665 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ DEGS1 O15121 1/20 0.38
▸ ESR1 P03372 3/20 0.37
▸ ESR2 Q92731 3/20 0.37
▸ PDCD1 Q15116 1/20 0.37
▸ CD274 Q9NZQ7 1/20 0.37
▸ RNASEH1 O60930 1/20 0.36
▸ CHRNA7 P36544 1/20 0.36
▸ CYP2C9 P11712 2/20 0.35
▸ NPC1 O15118 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603122 0.84 UGT2B7 (0.38) HIF1AALDH1A1LMNASMN1; SMN2ESR1
SCHEMBL1515159 0.82 ESR1 (0.34) ESR1ESR2PDCD1CD274
SCHEMBL22273322 0.82 ESR1 (0.35) HIF1ALMNAESR1ESR2PDCD1
SCHEMBL24609351 0.82 ESR1 (0.34) ESR1ESR2PDCD1CD274
SCHEMBL21142428 0.82 ESR1 (0.34) ESR1ESR2PDCD1CD274
SCHEMBL14239254 0.79 ALDH1A1 (0.46) PTGS1HTTALDH1A1GAALMNA
SCHEMBL11989537 0.79 DEGS1 (0.33) DEGS1ESR1ESR2PDCD1CD274
SCHEMBL1515610 0.76 EPHX1 (0.47) HTTGAADEGS1CHRNA7PTGS2
SCHEMBL24859291 0.76 ESR1 (0.38) PTGS1TRPA1ALDH1A1GAALMNA
SCHEMBL18891695 0.76 ESR1 (0.38) PTGS1TRPA1ALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 — — EP claimed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 — — US claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US claimed
US-12043613-B2 Inhibitors of SARM1 DISARM THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043613-B2 Inhibitors of SARM1 DISARM THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
WO-2024112123-A1 NOVEL COMPOUND AS SELECTIVE ESTROGEN RECEPTOR MODULATOR 재단법인 대구경북첨단의료산업진흥재단 2024-05-30 — — WO disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 — — WO disclosed
WO-2024044778-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF CELMATIX INC. (US) 2024-02-29 — — WO disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-20080146811-A1 Compounds and Methods For Treatment of Thrombosis DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC 2008-06-19 — — US disclosed
US-20080146811-A1 Compounds and Methods For Treatment of Thrombosis DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC 2008-06-19 — — US disclosed
US-7384947-B2 Fused tricyclic heterocycles useful for treating hyper-proliferative disorders BAYER HEALTHCARE LLC (US) 2008-06-10 — — US disclosed
US-7378418-B2 Azabicyclic heterocycles as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 — — US disclosed
US-7351735-B2 Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2008-04-01 — — US disclosed
US-20070259924-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2007-11-08 — — US disclosed
US-7189728-B2 Inhibitors of dipeptidyl peptidase IV FERRING, BV (NL) 2007-03-13 — — US disclosed
US-7189728-B2 Inhibitors of dipeptidyl peptidase IV FERRING, BV (NL) 2007-03-13 — — US disclosed
WO-2006012504-A2 COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS DAIAMED, INC. (US) 2006-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 TYR 2819/4885PTGS1 518/4885TRPA1 14/4885
US-20080146811-A1 Compounds and Methods For Treatment of Thrombosis F2, SERPINC1, PLAT TYR 544/4885PTGS1 195/4885TRPA1 3708/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS TYR 662/4885PTGS1 1214/4885TRPA1 3301/4885
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof AHR, ARNT, HCAR1 TYR 470/4885PTGS1 1206/4885TRPA1 399/4885
US-12043613-B2 Inhibitors of SARM1 SARM1, SMN1; SMN2, SARNP TYR 4227/4885PTGS1 4277/4885TRPA1 3581/4885
US-20070259924-A1 FACTOR XA INHIBITORS TFPI, F12, F11 TYR 2128/4885PTGS1 418/4885TRPA1 4009/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 TYR 2819/4885PTGS1 518/4885TRPA1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.